Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunologic Basis of Anti-IgE Therapy in Asthma
NCT00367016Phase 4Completed
- Sponsor
- University of California, Davis
- Start
- Feb 2004
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in asthma, allergic rhinitis (AR), atopic dermatitis (AD), sponsored by University of California, Davis. Started Feb 2004; status: completed.
02
Drugs
omalizumab
03
Conditions
asthmaallergic rhinitis (AR)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00367016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367016.